The role of sclerostin in the pathophysiology of sclerosing bone dysplasias

Clinical Reviews in Bone and Mineral Metabolism

Volumn 10, Issue 2, 2012, Pages 108-116

  Van Lierop, A H ^a   Hamdy, N A T ^a   Van Bezooijen, R L ^a   Lowik C W ^a   Papapoulos, S E ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Sclerosteosis; Sclerostin; Van Buchem disease

Indexed keywords

BETA CATENIN; DICKKOPF 1 PROTEIN; GLUCOCORTICOID; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; LYMPHOID ENHANCER FACTOR 1; OSTEOCLAST DIFFERENTIATION FACTOR; SCLEROSTIN; T CELL FACTOR PROTEIN; WNT PROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; BONE DYSPLASIA; BONE METABOLISM; BONE TURNOVER; BRAIN VENTRICLE PERITONEUM SHUNT; CARBOXY TERMINAL SEQUENCE; CARTILAGE CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CEMENTUM; DECOMPRESSION SURGERY; FACIAL NERVE PARALYSIS; GENE DELETION; HEARING LOSS; HUMAN; HYPEROSTOSIS; INTRACRANIAL HYPERTENSION; MINERAL METABOLISM; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; OSTEOSCLEROSIS; PHENOTYPE; POINT MUTATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; SYNDACTYLY; VAN BUCHEM DISEASE; WNT SIGNALING PATHWAY;

EID: 84861230356     PISSN: 15348644     EISSN: 15590119     Source Type: Journal    
DOI: 10.1007/s12018-011-9123-5     Document Type: Article

References (71)

1. Bonewald LF. The amazing osteocyte. J Bone Miner Res. 2011;26(2):229-38.
2. Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O'Brien CA. Matrix-embedded cells control osteoclast formation. Nat Med. 2011;17(10):1235-41.
3. Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-Hora M, Feng JQ, et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med. 2011;17(10):1231-4.
4. van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, et al. Sclerostin is an osteocyteexpressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med. 2004;199(6):805-14. (Pubitemid 38375200)
5. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397(6717):315-23.
6. Balemans W, Ebeling M, Patel N, Van HE, Olson P, Dioszegi M, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001;10(5):537-43. (Pubitemid 32184286)
7. Brunkow ME, Gardner JC, Van NJ, Paeper BW, Kovacevich BR, Proll S, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001;68(3):577-89. (Pubitemid 32202753)
8. Staehling-Hampton K, Proll S, Paeper BW, Zhao L, Charmley P, Brown A, et al. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet. 2002;110(2):144-52.
9. Balemans W, Patel N, Ebeling M, Van HE, Wuyts W, Lacza C, et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet. 2002;39(2):91-7. (Pubitemid 34146376)
10. Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Lowik CW, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 2005;19(13):1842-4. (Pubitemid 41598769)
11. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003;22(23):6267-76. (Pubitemid 37522584)
12. Chang M, Kramer I, Kneissel M. Sclerostin deficiency does not induce bone gain in mice lacking osteocyte beta-catenin. JBMR. 2011;26:S13.
13. Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One. 2011;6(10):e25900.
14. van Bezooijen RL, Bronckers AL, Gortzak RA, Hogendoorn PC, Wee-Pals L, Balemans W, et al. Sclerostin in mineralized matrices and van Buchem disease. J Dent Res. 2009;88(6):569-74.
15. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008;23(6):860-9. (Pubitemid 351768804)
16. Moester MJ, Papapoulos SE, Lowik CW, van Bezooijen RL. Sclerostin: current knowledge and future perspectives. Calcif Tissue Int. 2010;87(2):99-107.
17. Hamersma H, Gardner J, Beighton P. The natural history of sclerosteosis. Clin Genet. 2003;63(3):192-7. (Pubitemid 36949919)
18. Van Buchem FS. Hyperostosis corticalis generalisata. Eight new cases. Acta Med Scand. 1971;189(4):257-67.
19. Van Buchem FS, Hadders HN, Hansen JF, Woldring MG. Hyperostosis corticalis generalisata. Report of seven cases. Am J Med. 1962;33:387-97.
20. van Bezooijen RL, Svensson JP, Eefting D, Visser A, van der Horst G, Karperien M, et al. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res. 2007;22(1):19-28. (Pubitemid 46032593)
21. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005;280(20):19883-7. (Pubitemid 41379516)
22. Semenov M, Tamai K, He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem. 2005;280(29):26770-5. (Pubitemid 41040710)
23. Kubota T, Michigami T, Ozono K. Wnt signaling in bone metabolism. J Bone Miner Metab. 2009;27(3):265-71.
24. Mao B, Wu W, Davidson G, Marhold J, Li M, Mechler BM, et al. Kremen proteins are Dickkopf receptors that regulate Wnt/betacatenin signalling. Nature. 2002;417(6889):664-7. (Pubitemid 34614827)
25. Leupin O, Piters E, Halleux C, Hu S, Kramer I, Morvan F, et al. Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function. J Biol Chem. 2011;286(22):19489-500.
26. de Vernejoul MC. Sclerosing bone disorders. Best Pract Res Clin Rheumatol. 2008;22(1):71-83.
27. Truswell AS. Osteopetrosis with syndactyly; a morphological variant of Albers-Schonberg's disease. J Bone Joint Surg Br. 1958;40-B(2):209-18.
28. Balemans W, Cleiren E, Siebers U, Horst J, Van HW. A generalized skeletal hyperostosis in two siblings caused by a novel mutation in the SOST gene. Bone. 2005;36(6):943-7. (Pubitemid 40797994)
29. Piters E, Culha C, Moester M, Van BR, Adriaensen D, Mueller T, et al. First missense mutation in the SOST gene causing sclerosteosis by loss of sclerostin function. Hum Mutat. 2010;31(7):E1526-43.
30. Beighton P, Davidson J, Durr L, Hamersma H. Sclerosteosis-an autosomal recessive disorder. Clin Genet. 1977;11(1):1-7.
31. Van Buchem FS, Hadders HN, Ubbens R. An uncommon familial systemic disease of the skeleton: hyperostosis corticalis generalisata familiaris. Acta Radiol. 1955;44(2):109-20.
32. Loots GG, Kneissel M, Keller H, Baptist M, Chang J, Collette NM, et al. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res. 2005;15(7):928-35. (Pubitemid 40994212)
33. Wengenroth M, Vasvari G, Federspil PA, Mair J, Schneider P, Stippich C. Case 150: Van Buchem disease (hyperostosis corticalis generalisata). Radiology. 2009;253(1):272-6.
34. Beighton P, Durr L, Hamersma H. The clinical features of sclerosteosis. A review of the manifestations in twenty-five affected individuals. Ann Intern Med. 1976;84(4):393-7.
35. van Lierop AH, Hamdy NA, Hamersma H, van Bezooijen RL, Power J, Loveridge N, et al. Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. J Bone Miner Res. 2011;26(12):2804-11.
36. Epstein S, Hamersma H, Beighton P. Endocrine function in sclerosteosis. S Afr Med J. 1979;55(27):1105-10. (Pubitemid 9204269)
37. Stein SA, Witkop C, Hill S, Fallon MD, Viernstein L, Gucer G, et al. Sclerosteosis: neurogenetic and pathophysiologic analysis of an American kinship. Neurology. 1983;33(3):267-77. (Pubitemid 13155755)
38. Barnard AH, Hamersma H, Kretzmar JH, Beighton P. Sclerosteosis in old age. S Afr Med J. 1980;58(10):401-3. (Pubitemid 10003628)
39. Beighton P, Barnard A, Hamersma H, van der Wouden A. The syndromic status of sclerosteosis and van Buchem disease. Clin Genet. 1984;25(2):175-81. (Pubitemid 14187397)
40. Van HW, Balemans W, Van HE, Dikkers FG, Obee H, Stokroos RJ, et al. Van Buchem disease (hyperostosis corticalis generalisata) maps to chromosome 17q12-q21. Am J Hum Genet. 1998;62(2):391-9. (Pubitemid 28110782)
41. Vanhoenacker FM, Balemans W, Tan GJ, Dikkers FG, De Schepper AM, Mathysen DG, et al. Van Buchem disease: lifetime evolution of radioclinical features. Skeletal Radiol. 2003;32(12):708-18. (Pubitemid 37527086)
42. van Lierop AH, Hamdy NA, Papapoulos SE. Glucocorticoids are not always deleterious for bone. J Bone Miner Res. 2010;25(12):2796-800.
43. Wergedal JE, Veskovic K, Hellan M, Nyght C, Balemans W, Libanati C, et al. Patients with Van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal. J Clin Endocrinol Metab. 2003;88(12):5778-83. (Pubitemid 38033050)
44. Beighton P, Cremin BJ, Hamersma H. The radiology of sclerosteosis. Br J Radiol. 1976;49(587):934-9.
45. Hill SC, Stein SA, Dwyer A, Altman J, Dorwart R, Doppman J. Cranial CT findings in sclerosteosis. AJNR Am J Neuroradiol. 1986;7(3):505-11. (Pubitemid 16083439)
46. du Plessis JJ. Sclerosteosis: neurosurgical experience with 14 cases. J Neurosurg. 1993;78(3):388-92. (Pubitemid 23073207)
47. Modder UI, Clowes JA, Hoey K, Peterson JM, McCready L, Oursler MJ, et al. Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res. 2011;26(1):27-34.
48. Modder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL, et al. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res. 2011;26(2):373-9.
49. Kirmani S, Amin S, McCready LK, Atkinson EJ, Melton LJ, III, Muller R, et al. Sclerostin levels during growth in children. Osteoporos Int. (2011) (epub).
50. Weidauer SE, Schmieder P, Beerbaum M, Schmitz W, Oschkinat H, Mueller TD. NMR structure of the Wnt modulator protein Sclerostin. Biochem Biophys Res Commun. 2009;380(1):160-5.
51. Veverka V, Henry AJ, Slocombe PM, Ventom A, Mulloy B, Muskett FW, et al. Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation. J Biol Chem. 2009;284(16):10890-900.
52. McNulty M, Singh RJ, Li X, Bergstralh EJ, Kumar R. Determination of serum and plasma sclerostin concentrations by enzymelinked immunoassays. J Clin Endocrinol Metab. 2011;96(7):E1159-62.
53. Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MR, Alam I, et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem. 2008;283(9):5866-75.
54. Lin C, Jiang X, Dai Z, Guo X, Weng T, Wang J, et al. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling. J Bone Miner Res. 2009;24(10):1651-61.
55. Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, Mangiafico RA, et al. Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab. 2010;95(5):2248-53.
56. Morse LR, Sudhakar S, Danilack V, Tun C, Lazzari A, Gagnon DR, et al. Association between sclerostin and bone density in chronic SCI. J Bone Miner Res. (2011) (epub).
57. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O'Brien CA, et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology. 2005;146(11):4577-83. (Pubitemid 41446595)
58. Silvestrini G, Ballanti P, Leopizzi M, Sebastiani M, Berni S, Di VM, et al. Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone. J Mol Histol. 2007;38(4):261-9. (Pubitemid 47106897)
59. van Lierop AH, Witteveen JE, Hamdy NA, Papapoulos SE. Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls. Eur J Endocrinol. 2010;163(5):833-7.
60. Drake MT, Srinivasan B, Modder UI, Peterson JM, McCready LK, Riggs BL, et al. Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab. 2010;95(11):5056-62.
61. Vincent C, Findlay DM, Welldon KJ, Wijenayaka AR, Zheng TS, Haynes DR, et al. Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogenactivated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J Bone Miner Res. 2009;24(8):1434-49.
62. Appel H, Ruiz-Heiland G, Listing J, Zwerina J, Herrmann M, Mueller R, et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthr Rheum. 2009;60(11):3257-62.
63. Mabilleau G, Mieczkowska A, Edmonds ME. Thiazolidinediones induce osteocyte apoptosis and increase sclerostin expression. Diabet Med. 2010;27(8):925-32.
64. Yao W, Cheng Z, Busse C, Pham A, Nakamura MC, Lane NE. Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. Arthr Rheum. 2008;58(6):1674-86. (Pubitemid 351847520)
65. Gardner JC, van Bezooijen RL, Mervis B, Hamdy NA, Lowik CW, Hamersma H, et al. Bone mineral density in sclerosteosis; affected individuals and gene carriers. J Clin Endocrinol Metab. 2005;90(12):6392-5. (Pubitemid 41759290)
66. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009;24(4):578-88.
67. Ominsky MS, Vlasseros F, Jolette J, Smith SY, Stouch B, Doellgast G, et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res. 2010;25(5):948-59.
68. Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011;26(1):19-26.
69. Marenzana M, Greenslade K, Eddleston A, Okoye R, Marshall D, Moore A, et al. Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone. Arthr Rheum. 2011;63(8):2385-95.
70. Eddleston A, Marenzana M, Moore AR, Stephens P, Muzylak M, Marshall D, et al. A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis. J Bone Miner Res. 2009;24(10):1662-71.
71. Ominsky MS, Li C, Li X, Tan HL, Lee E, Barrero M, et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res. 2011;26(5):1012-21.